SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)

NEW YORK, Feb. 18, 2021/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ofAcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company")(NASDAQ: ACRX).A A  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.comor 888-476-6529, ext. 7980.The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.A  [Click here for information about joining the class action]On February 16, 2021, AcelRx received a warning letter from the U.S. Food & Drug Administration ("FDA") concerning the promotional claims for the Company's pain medication Dsuvia (sufentanil).A  Specifically, having "reviewed an "SDS Banner Ad" (banner) (PM-US-DSV-0018) and a tabletop display (PM-US-DSV-0049) (display)," the FDA concluded that "[t]he promotional communications, the banner and display, make false or misleading claims and representations about the risks and efficacy of DSUVIA," and "[t]hus . . . misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative."A  The warning letter "requests that AcelRx cease any violations of the FD&C Act" and "submit a written response to this letter within 15 days from the date of receipt[.]"A 
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »